Repertoire Immune Medicines expanded its pharma partnerships by signing Eli Lilly to a collaboration focused on tolerizing vaccines for autoimmune diseases, in a deal that could be worth up to multibillion dollars. The company’s immune‑system decoding platform will work with Lilly to develop antigen‑specific tolerogenic approaches aimed at reprogramming autoreactive responses. Repertoire’s platform pairs high‑throughput antigen discovery with cell‑state mapping to design therapeutic modalities intended to induce durable immune tolerance. The agreement represents continued validation of Repertoire’s technology by major pharma partners and adds scale to a growing set of industry collaborations exploring antigen‑targeted immune modulation.